» Articles » PMID: 36768818

Integrated Microarray-Based Data Analysis of MiRNA Expression Profiles: Identification of Novel Biomarkers of Cisplatin-Resistance in Testicular Germ Cell Tumours

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Feb 11
PMID 36768818
Authors
Affiliations
Soon will be listed here.
Abstract

Testicular germ cell tumours (TGCTs) are the most common solid malignancy among young men, and their incidence is still increasing. Despite good curability with cisplatin (CDDP)-based chemotherapy, about 10% of TGCTs are non-responsive and show a chemoresistant phenotype. To further increase TGCT curability, better prediction of risk of relapse and early detection of refractory cases is needed. Therefore, to diagnose this malignancy more precisely, stratify patients more accurately and improve decision-making on treatment modality, new biomarkers are still required. Numerous studies showed association of differential expressions of microRNAs (miRNAs) with cancer. Using microarray analysis followed by RT-qPCR validation, we identified specific miRNA expression patterns that discriminate chemoresistant phenotypes in TGCTs. Comparing CDDP-resistant vs. -sensitive TGCT cell lines, we identified miR-218-5p, miR-31-5p, miR-125b-5p, miR-27b-3p, miR-199a-5p, miR-214-3p, let-7a and miR-517a-3p as significantly up-regulated and miR-374b-5p, miR-378a-3p, miR-20b-5p and miR-30e-3p as significantly down-regulated. In patient tumour samples, we observed the highest median values of relative expression of miR-218-5p, miR-31-5p, miR-375-5p and miR-517a-3p, but also miR-20b-5p and miR-378a-3p, in metastatic tumour samples when compared with primary tumour or control samples. In TGCT patient plasma samples, we detected increased expression of miR-218-5p, miR-31-5p, miR-517a-3p and miR-375-5p when compared to healthy individuals. We propose that miR-218-5p, miR-31-5p, miR-375-5p, miR-517-3p, miR-20b-5p and miR-378a-3p represent a new panel of biomarkers for better prediction of chemoresistance and more aggressive phenotypes potentially underlying metastatic spread in non-seminomatous TGCTs. In addition, we provide predictions of the targets and functional and regulatory networks of selected miRNAs.

Citing Articles

Exploring miRNA profile associated with cisplatin resistance in ovarian cancer cells.

Alghamian Y, Soukkarieh C, Aljapawe A, Murad H Biochem Biophys Rep. 2025; 41():101906.

PMID: 39830525 PMC: 11741906. DOI: 10.1016/j.bbrep.2024.101906.


Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia.

Karabay A, Ozkan T, Karadag Gurel A, Koc A, Hekmatshoar Y, Sunguroglu A Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9701-9721.

PMID: 38916832 PMC: 11582232. DOI: 10.1007/s00210-024-03198-1.


Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.

Urbini M, Bleve S, Schepisi G, Menna C, Gurioli G, Gianni C Int J Mol Sci. 2023; 24(23).

PMID: 38069192 PMC: 10706346. DOI: 10.3390/ijms242316872.


Epigenetic Factors and ncRNAs in Testicular Cancer.

Nunez-Corona D, Contreras-Sanzon E, Puente-Rivera J, Arreola R, Camacho-Nuez M, Cruz Santiago J Int J Mol Sci. 2023; 24(15).

PMID: 37569569 PMC: 10418327. DOI: 10.3390/ijms241512194.


Breaking the Mold: Epigenetics and Genomics Approaches Addressing Novel Treatments and Chemoresponse in TGCT Patients.

Cuevas-Estrada B, Montalvo-Casimiro M, Munguia-Garza P, Rios-Rodriguez J, Gonzalez-Barrios R, Herrera L Int J Mol Sci. 2023; 24(9).

PMID: 37175579 PMC: 10178517. DOI: 10.3390/ijms24097873.

References
1.
Li H, Wei J, Fan L, Wang S, Zhu L, Li T . miR-302 regulates pluripotency, teratoma formation and differentiation in stem cells via an AKT1/OCT4-dependent manner. Cell Death Dis. 2016; 7:e2078. PMC: 4816169. DOI: 10.1038/cddis.2015.383. View

2.
De Martino M, Esposito F, Pellecchia S, Penha R, Botti G, Fusco A . HMGA1-Regulating microRNAs Let-7a and miR-26a are Downregulated in Human Seminomas. Int J Mol Sci. 2020; 21(8). PMC: 7215726. DOI: 10.3390/ijms21083014. View

3.
Lobo J, Gillis A, van den Berg A, Dorssers L, Belge G, Dieckmann K . Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data. Cells. 2019; 8(12). PMC: 6952794. DOI: 10.3390/cells8121637. View

4.
Mueller T, Mueller L, Luetzkendorf J, Voigt W, Simon H, Schmoll H . Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumour Biol. 2006; 27(2):71-83. DOI: 10.1159/000092324. View

5.
Le Cornet C, Lortet-Tieulent J, Forman D, Beranger R, Flechon A, Fervers B . Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data. Eur J Cancer. 2013; 50(4):831-9. DOI: 10.1016/j.ejca.2013.11.035. View